SOURCE: Draco Healthcare Consulting, LLC

Draco Healthcare Consulting, LLC - a China Focused Company

September 22, 2009 09:00 ET

Draco's 2009 Executive Summary of the Chinese Pharmaceutical Market: Is it Still an Emerging Market or Already a Big Market?

FREMONT, CA--(Marketwire - September 22, 2009) - Draco Healthcare Consulting LLC, a leading China-focused healthcare consulting firm, announced the launch of the China Pharma Executive Summary 2009, which indicates that the total Chinese pharmaceutical market had reached RMB 828.36 billion (US $120.84 billion) in 2008. The AAGR of 26.50% of the rapidly-expanding Chinese pharmaceutical market is no doubt astonishingly high, especially in the midst of the global cry of economic deterioration.

China has been labeled as an "emerging" country whenever emerging markets are mentioned. The word "emerging" has put many people at ease since people are still locking their eyes at the "mature" pharmaceutical markets including US, Europe and Japan.

"The Chinese pharmaceutical market is of high interest to us; however, the number is too small to be on our radar screen, compared to that of the seven mature markets," said one Wall Street analyst during an interview with Dr. Linda Zhao, CEO of Draco Healthcare. "What people are missing is that the number, whatever it is, may underestimate the Chinese pharmaceutical market, which is largely a generic drug market that has significant domestic demands; therefore, a significant portion of the Chinese pharmaceutical market is not counted by the outside world," said Dr. Zhao.

The China Pharma Executive Summary 2009 contains the market sizes of specific therapeutic areas in China, including asthma, cancer, liver diseases, diabetes, hypertension, depression, allergy, senile-dementia, benign prostate hyperplasia, ophthalmology, hyperlipoidemia, rheumatoid arthritis, dermatitis, and blood products etc. Key players and drugs in each area are also listed. All data are based on hospital prescription data collected from sampled hospitals in major Chinese cities, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, Xian, Shenyang, Harbin and Zhengzhou with a high coverage of hospital beds and out-patients.

This China Pharma Executive Summary has been a must-have reference for all levels of decision maker in pharmaceutical companies, medical device companies, healthcare investing companies and healthcare consulting companies. These unique market data provide valuable information for product development, marketing, forecasting, strategic planning and competition analysis.

About Draco Healthcare Consulting, LLC

Draco focuses exclusively on the Chinese pharmaceutical market, providing consulting services to world pharmaceutical companies. Draco publishes proprietary annual China Drug Reports of Chinese hospital prescription/purchasing data, Chinese Epidemiology Data, China Cancer Treatment Reports and China Hospital Report.

Contact Information